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Thyroid Autoimmunity and Function
after Treatment with Biological 
Antirheumatic Agents in  
Rheumatoid Arthritis
 
Sofie Bliddal†, Stina Willemoes Borresen† and Ulla Feldt-Rasmussen*
Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
With the increased pro-inflammatory response in both rheumatoid arthritis and thyroid 
autoimmune diseases, treatment with biological antirheumatic agents (BAAs) of the 
former may affect the course of the latter. In hepatitis C and cancer patients, treatment 
with biological agents substantially increases the risk of developing thyroid autoimmunity. 
As the use of BAAs in the treatment of rheumatoid arthritis is increasing, this review 
aimed to investigate if such use affected thyroid status in rheumatoid arthritis patients. 
We conducted a systematic literature search and included six studies with a total of 311 
patients as well as three case reports. The patients were treated with tumor necrosis fac-
tor-α inhibitors (infliximab, etanercept, or adalimumab) or the monoclonal CD20-antibody 
rituximab. There was a non-significant trend of slight improvement of both thyroid 
function and autoantibody status: a reduction of thyroid peroxidase and thyroglobulin 
antibody concentrations, and a reduction of thyrotropin levels in hypothyroid patients. 
Despite the small number of studies, they presented compliant data. The BAAs used in 
rheumatoid arthritis thus did not seem to negatively affect thyroid status in patients with 
rheumatoid arthritis and can be considered safe with regard to thyroid autoimmunity. 
However, the well-established association between rheumatic diseases and thyroid 
autoimmunity necessitates continued monitoring of thyroid function in patients with 
rheumatoid arthritis. Each new BAA should be scrutinized for its effect on thyroid as 
well as other autoimmune diseases in order to establish concise recommendations for 
patient follow-up for each agent and each disease.
Keywords: autoimmune thyroiditis, rheumatoid arthritis, biological antirheumatic agents, Hashimoto’s thyroiditis, 
Graves’ disease, thyroperoxidase antibody, thyroglobulin antibody, tumor necrosis factor-alpha inhibitors
inTRODUCTiOn
Autoimmune thyroid diseases are the most common autoimmune diseases and are often associ-
ated with the presence of other organ-specific or non-organ-specific autoimmune diseases (1). 
The coexistence of thyroid autoimmunity and rheumatoid arthritis has been acknowledged for 
over a century (2). Population studies have confirmed an increased prevalence of autoimmune 
thyroid disease in patients with rheumatoid arthritis and conversely, an increased prevalence of 
rheumatoid arthritis in patients with autoimmune thyroid disease (3, 4). Boelaert et al. (5) asked 
3,286 thyroid patients to report other autoimmune diagnoses among themselves and their rela-
tives. Rheumatoid arthritis was the most prevalent coexisting autoimmune disease occurring in 
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3.15% of patients with Graves’ disease and 4.24% of patients with 
Hashimoto’s thyroiditis (5). Similarly, Fallahi et al. (6) found a 
2.4% prevalence of rheumatoid arthritis in 3,069 patients with 
verified autoimmune thyroiditis, which was significantly higher 
than in patients with multinodular goiter and in thyroid-healthy 
age- and sex-matched controls (p < 0.0001). In a recent meta-
analysis (7), patients with rheumatoid arthritis had a three times 
higher risk of having thyroid autoantibodies than healthy con-
trols [thyroglobulin autoantibody (TgAb): OR 3.17 (2.24–4.49) 
and thyroglobulin autoantibody (TPOAb): OR 2.33 (1.24–4.39)].
Although an association between thyroid autoimmunity and 
rheumatoid arthritis has been demonstrated, the causality is not 
yet established. However, there is increasing awareness of a pos-
sible common pathogenesis behind autoimmune diseases poten-
tially caused by an underlying immunological breach resulting in 
disruption of self-tolerance (8). It is generally believed that both 
autoimmune thyroid disease and rheumatoid arthritis occur as 
a result of multiple factors (genetic susceptibility, endogenous, 
and environmental) (1, 9, 10). A malfunctioning T and B  cell 
regulation causing reactions against autoantigens is involved 
in both conditions with antibody production in rheumatoid 
arthritis (rheumatoid factor and anti-cyclic citrullinated peptide) 
and thyroid autoimmunity (thyroid peroxidase, thyroglobulin, 
and thyroid stimulating hormone receptor antibodies) (1). Such 
T and B  cell regulation is highly complex, but is intertwined 
with expression of various cytokines. Both cytokine production 
and B  cell function are among the targets of newer biological 
antirheumatic agents (BAAs), which are increasingly used in the 
treatment of rheumatoid arthritis (11, 12). Current guidelines 
generally recommend treatment with BAAs when there is either 
insufficient response to treatment with the conventional disease 
modifying antirheumatic drugs or in the presence of unfavorable 
prognostic markers (autoantibodies, high disease activity, early 
erosions, and failure of two conventional disease modifying 
antirheumatic drugs) (11, 12). Although an increasing amount of 
antirheumatic agents exist, the most commonly used in the treat-
ment of rheumatoid arthritis is the group of inhibitors of tumor 
necrosis factor-α (TNF-α). This pro-inflammatory cytokine plays 
a vital role in the immunological activation related to the auto-
immune inflammatory patterns in rheumatoid arthritis. TNF-α 
expression has also been shown to be increased in patients with 
autoimmune thyroid disease, and therefore, treatment with TNF-
α inhibitors could possibly effect thyroid autoimmune status as 
well (13). In previous studies of older immunomodulatory agents 
(e.g., interferon-α) in patients with multiple sclerosis and hepatitis 
C, it has long been known that thyroid autoimmunity develop in 
more than one-third of such patients (14–16). A mutual affec-
tion of the immune system in rheumatoid arthritis and thyroid 
autoimmunity makes the use of BAAs relevant also within the 
field of thyroid autoimmunity. The present review investigates 
the association between biological antirheumatic treatment of 
rheumatoid arthritis and affection of thyroid autoimmunity.
MeTHODS
In March 2017, a Medline literature search was performed using 
key terms of “rheumatoid arthritis,” “thyroid,” and alternately 
generic and commercial names of known BAAs. Identified 
studies were initially screened by title and abstract, and full 
text retrieved for further scrutiny. Further, the reference lists of 
included studies were checked. Only original studies evaluat-
ing thyroid autoimmunity during treatment with BAAs for 
rheumatoid arthritis were eligible for inclusion. Case reports 
were included and presented separately. All relevant data were 
carefully extracted from each included paper and txabulated 
independently by two authors (Sofie Bliddal and Stina Willemoes 
Borresen). Extracted data included: first author, publication year, 
number of patients, the studied BAA, patients’ other medication, 
follow-up, method and cut-off used for detecting thyroid anti-
bodies, known autoimmune thyroid disease, and thyroid status 
including autoimmunity before and after treatment with the BAA. 
Any disagreements were resolved by consensus. In some studies, 
the proportion of patients with positive thyroid antibodies was 
not reported directly, but could be calculated from study data.
ReSULTS
Study Characteristics
A total of 14 relevant articles were identified. Upon scrutiny, five 
articles failed to comply with the inclusion criteria or had insuf-
ficient outcome reports of thyroid status, leaving six included 
articles (17–22), in a total 311 patients, and three were case reports 
(23–25). The studies included five prospective cohort studies of 
previous BAA-naïve patients with rheumatoid arthritis (17–20, 22) 
and one cross-sectional study of patients with rheumatoid arthri-
tis who had received treatment with BAAs (Table 1) (21). The 
TNF-α inhibitors adalimumab (ADM), infliximab (INX), and 
etanercept (ETC) were used in three (17, 21, 22), four (18–21), 
and two (18, 21) studies, respectively. The monoclonal CD20 
antibody rituximab (RIX) was used in two studies (20, 21). One 
of these was a cross-sectional study (21) and the other did not 
stratify results from patients treated with RIX from results of 
patients treated with the TNF-α inhibitor INX (20). One study 
(20) excluded patients with previously known thyroid disease, 
three studies (17, 21, 22) and two studies (18, 19) did not report 
whether they excluded these patients. All six studies reported 
the number of TPOAb-positive patients, and three studies 
(17, 20, 21) reported TgAb positivity. Additionally, two studies 
(20, 22) reported the TPOAb levels and one study (20) reported 
the TgAb levels. Two studies (20, 22) reported mean TSH and free 
thyroxine (FT4) levels.
Thyroid Autoimmunity
Biological antirheumatic treatment did not seem to affect the 
number of TPOAb-positive patients, which varied from 0 to 30% 
of patients at baseline and 0 to 25% at follow-up (Figure  1A; 
Table 1). Two studies reported a single patient turning TPOAb-
positive after treatment with ADM (17, 22), and the number of 
TPOAb-positive patients was unchanged in two studies of INX 
(19) or INX/RIX (20), respectively. Likewise, only one TgAb-
positive patient turned antibody-negative and none in a study of 
ADM (17) (Figure 1B). In the study of Caramaschi et al. (18), six 
patients treated with INX shifted from negative to positive thy-
roid antibodies and four patients shifted from positive to negative 
TABLe 1 | Studies of thyroid status in rheumatoid arthritis patients treated with BAAs.
Reference Study group BAA Dosage Other treatment Antibody 
assay
Antibody 
cut-off
Baseline Follow-up 
time
Outcome
 Antibody positivity Thyroid function Antibody 
positivity
Thyroid function
Atzeni  
et al. (17)
20 RA pts  
(17 women)
ADM 40 mg/2 weeks MTX: 20/20  
(100%)
GC: 13/20 (65%)
NSAID: 14/20  
(70%)
ICMA 
(immulite 
2000, DPC)
TPOAb: 35  
IU/mL
TgAb: 40  
IU/mL
TPOAb: 6/20 (30%)
TgAb: 8/20 (40%)
HT: 3/20 (15%) 6 months TPOAb: 5/20  
(25%)
TgAb: 8/20  
(40%)
NA
Caramaschi 
et al. (18)
54 RA pts  
(46 women)
INX n = 43
ETC n = 11
INX 3 mg/kg on 
week 0, 2, 6 and  
every 8 weeks
MTX: 52/54 (96%)
Azathioprine: 2/54 
(4%)
ELISA TPOAb: 35  
IU/mL
TgAb: 40  
IU/mL
TPOAb: 6/54 (11%)
TgAb: 7/54 (13%)
+4 Ab positive ptsa
NA 12 months TPOAb: 6/54 
(11%),
TgAb: 7/54 (13%) 
(12 INX, 1 ETC)
Shift Ab-neg to 
Ab-pos: 6 pts
Shift Ab-pos to 
Ab-neg: 4 pts  
(INX)a
All euthyroid
ETC 2 × 25 mg/week
Elkayam  
et al. (19)
26 RA pts  
(17 women)
INX 3 mg/kg on week 0, 2, 
6, and every 8 weeks
MTX 26/26 (100%) ELISA (Zeus 
Scientific)
TPOAb: 25  
IU/mL
TPOAb: 0/26 NA 14 weeks TPOAb: 0/26 NA
Kaklamanos 
et al. (20)
36 rheumatic 
ptsb (28 
women)
INX n = 18  
(14 RA pts)
RIX n = 18  
(12 RA pts)
INX 200, 350, or  
500 mg
RIX 
2 × 1,000 mg/2 weeks 
or 4 × 500 mg/week
MTX: 13/36 (36%)
Prednisolone:  
16/36 (44%)
Leflunomide: 3/36 
(8%)
HCQ: 2/36 (6%)
CMIA 
(Architect 
i2000,  
Abbott)
TPOAb: 
5.61 IU/mL
TgAb: 4.11  
IU/mL
TPOAb: 4/36 (11%)
TgAb: 6/36 (17%)\
TPOAb level 
(mean ± SD): 
36.8 ± 44.9
TgAb level 
(mean ± SD): 
10.6 ± 7.1
TSH (mean ± SD): 
1.7 ± 1.2 mU/L
FT4 (mean ± SD): 
15.3 ± 3.7 pmol/L
3 years TPOAb: 4/36  
(11%)
TgAb: 5/36  
(14%)
TPOAb level 
(mean ± SD): 
20.2 ± 16.7
TgAb level 
(mean ± SD): 
9.3 ± 5.5
TSH (mean ± SD): 
1.8 ± 1.2 mU/L
FT4 (mean ± SD): 
15.4 ± 3.6 pmol/L
Koszarny 
et al. (21)
37 RA pts with 
a history of 
BAA treatmentc
INX, ETC,  
ADM, or RIXd
NA MTX, other 
DMARDs, 
prednisoloned 
ELISA 
(Euroimmun)
TPOAb: 50  
IU/mL
TgAb: 100  
IU/mL
TRAb: 2  
IU/mL
NA NA NA (cross-
sectional)
TPOAb: 4/37  
(11%)
TgAb: 2/37 (5%)
NA
Raterman 
et al. (22)
138 RA pts  
with known 
thyroid status 
(106 women)
ADM NA MTX 108/138  
(78%)
Prednisolone  
47/138 (34%)
ELISA 
(Cobas® 
analyzer)
TPOAb: 34  
IU/mL
TPOAb: 21/138  
(15%)
TPOAb level  
(median): 267 IU/mL
Mean TSH: 
1.5 mU/L
6 months TPOAb: 20/138 
(15%)
TPOAb level 
201 IU/mL*
Mean TSH: 
1.3 mU/L*
No. DMARDs  
used: 2–6
(Continued )
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Reference Study group BAA Dosage Other treatment Antibody 
assay
Antibody 
cut-off
Baseline Follow-up 
time
Outcome
 Antibody positivity Thyroid function Antibody 
positivity
Thyroid function
Hypothyroid pts TPOAb: 11/18  
(61%)
18/138 (13%) 6 months TPOAb: 12/18 
(67%)
16/138 (12%)
TPOAb level  
(median): 325  
IU/mL
Mean TSH: 
4.1 mU/L
TPOAb level 
(median) 282  
IU/mL
Mean TSH: 
3.5 mU/L
Euthyroid pts TPOAb: 9/113  
(8%)
113/138 (82%) 6 months TPOAb: 7/113  
(6%)
7/138 (5%)
TPOAb level  
(median): 114 IU/mL
Mean TSH: 
1.4 mU/L
TPOAb level 
(median) 108  
IU/mL
Mean TSH: 
1.3 mU/L
Hyperthyroid 
pts
TPOAb: 1/7 (14%) 7/138 (5%) 6 months TPOAb: 1/7  
(14%)
7/138 (5%)
TPOAb level: 73  
IU/mL
Mean TSH: 
0.5 mU/L
TPOAb level  
49 IU/mL
Mean TSH: 
0.5 mU/L
aNot reported whether TPOAb and/or TgAb.
bTwenty-six patients with RA, six patients with SLE, four patients with sero-negative arthritis. The study further included three different control groups.
cThe number of female patients not reported. The study also included 38 patients BAA-naïve RA patients.
dThe number of patients treated with each drug not reported.
*p < 0.05 compared to baseline data.
ADM, adalimumab; BAAs, biological antirheumatic agents; CMIA, Chemiluminescent microparticle immunoassay; ETC, etanercept; HCQ, Hydroxychloroquine; FT4, free thyroxine; HT, Hashimoto’s thyroiditis; ICMA, 
immunochemiluminescence assay; INX, infliximab; MTX, methotrexate; NA, data not available; pts, patients; RA, rheumatoid arthritis; RIX, rituximab; TgAbs, thyroglobulin autoantibodies; TPOAbs, thyroid peroxidase autoantibodies; 
TRAbs, thyrotropin receptor autoantibodies.
TABLe 1 | Continued
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FiGURe 1 | Proportion of TPOAb-positive (A) and TgAb-positive (B) patients at baseline and follow-up in patients with rheumatoid arthritis treated with biological 
antirheumatic agents (BAAs). Studies are presented by first author name (reference number) (BAA). *In four patients at baseline and six patients at follow-up, no 
distinction was made between TPOAb-positivity and TgAb-positivity, and thus the reported thyroid autoantibody prevalence was included in both Figures 1A,B. 
Abbreviations: ADM, adalimumab; ETC, etanercept; INX, infliximab; RIX, rituximab; NA, not available. TgAb, thyroglobulin autoantibody; TPOAb, thyroid peroxidase 
autoantibody.
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antibodies (no distinction was made between TPOAb and TgAb 
positivity). In a cross-sectional study (21), TPOAb-positivity 
was found in 4/37 (11%) patients with a history of biological 
antirheumatic treatment, which was similar to the 3/38 (8%) 
of patients who were BAA-naïve. The corresponding numbers 
of TgAb-positive patients were 2/37 (5%) and 4/38 (11%) for 
patients who had or had not received biological antirheumatic 
treatment, respectively.
Decreased or unchanged thyroid antibody levels were 
reported in two studies. In Raterman et al. (22), the mean TPOAb 
concentration decreased from 267 to 201 IU/mL (p = 0.048) in 
TPOAb-positive patients after 6 months of treatment with ADM. 
In Kaklamanos et al. (20), mean TPOAb concentration decreased 
insignificantly from 36.8 to 20.2  IU/mL in TPOAb-positive 
patients after 24–40 months treatment with INX or RIX. Likewise, 
mean TgAb concentration was unaffected in TgAb-positive 
patients (mean TgAb level 10.6–9.3 IU/mL) (20).
Thyroid Function
Two studies investigated changes in thyroid function before and 
after biological antirheumatic treatment (20, 22). In Raterman 
et al. (22), treatment with ADM led to a decrease in mean TSH 
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level from 1.5 to 1.3 mU/L (p = 0.0014) in the total group, whereas 
FT4 levels did not change. The decrease in TSH was larger in 
(previous) hypothyroid patients compared with euthyroid 
patients, but TSH also decreased in 8/10 of the hypothyroid 
patients who were not treated with l-thyroxine. Two of these 
patients became euthyroid after 6 months treatment with ADM 
(22). In Kaklamanos et al. (20), mean TSH changed from 1.7 to 
1.8 IU/L, and FT4 changed from 15.3 to 15.4 pmol/L, yet both 
not significantly.
Cases
Our search revealed three case reports of autoimmune thyroiditis 
in patients with rheumatoid arthritis treated with a BAA. Two 
cases (23, 24) reported hyperthyroidism in patients treated with 
anti-TNFα. The first case (23) reported transient hyperthyroid-
ism, lasting 1  month, in a patient after 6  months of treatment 
with ETC (TPOAb and TgAb negative, TRAb not measured). In a 
second case report (24), a 70-year-old women developed Graves’ 
disease after 8 years of treatment with ADM. Interestingly, one 
case reported improvement of previously known autoimmune 
hypothyroidism in a patient after treatment with RIX (25). 
TPOAbs declined to undetectable levels after 6 months of treat-
ment with RIX, and in an unchanged l-thyroxine dose the patient 
became clinically hyperthyroid with a TSH decline from 1.18 to 
0.10 mU/L (25).
DiSCUSSiOn
The present review showed that the BAAs used to treat rheu-
matoid arthritis did not seem to induce or worsen autoimmune 
thyroid disease. On the contrary, there was a tendency toward a 
positive effect; a reduction of TPOAb and TgAb concentrations 
and a reduction of TSH levels in hypothyroid patients. Despite the 
small number of included studies with diverse immunomodula-
tory agents (mainly TNF-α inhibitors, a few of RIX), the studies 
presented compliant data.
Due to its multiple immunological mechanisms, TNF-α has 
been previously investigated in thyroid patients. Both hypo- and 
hyperthyroid patients had significantly higher levels of TNF-α 
compared to controls, and in hyperthyroid patients successful 
treatment led to normalization of TNF-α levels (13). However, 
as demonstrated in the cases reported by van Lieshout (24) and 
Allanore (23), hyperthyroidism was diagnosed after initiation of 
anti-TNF-α therapy. It is difficult to assess whether this could 
be attributed to the treatment or an incidental finding due to 
a general susceptibility toward autoimmune thyroid disease in 
patients with rheumatoid arthritis (8). Also, autoimmune thy-
roid disease has been previously reported to fluctuate between 
hypo- and hyperthyroidism according to the prevailing subtype 
of (stimulating or blocking) thyrotropin receptor antibodies 
(26). These were not measured in the studies included in this 
review. Based on the results in the present review, alterations in 
thyroid autoimmune status upon anti-TNF-α treatment seem 
to be a minor concern and may very well be overshadowed by 
the potential benefit of such treatment—both in regard to the 
rheumatoid disease and possibly the thyroid autoimmune status.
Use of RIX, a monoclonal CD20 antibody causing B-cell-
depletion, did not lead to significant changes in thyroid status 
or autoimmunity (TPOAbs/TgAbs) in the study by Kaklamanos 
et al. (20). In the case by Raterman et al. (25), treatment with RIX 
for rheumatoid arthritis may have affected the coexisting autoim-
mune hypothyroidism causing a shift to a (iatrogenic) hyperthy-
roid state after a few months of treatment with RIX and unchanged 
l-thyroxine dose. However, thyrotropin receptor antibody levels 
were not reported in the studies and no distinction was made 
between thyroid disease entities (Hashimoto’s vs. Graves’ disease). 
In Graves’ disease complicated by moderate/severe orbitopathy, 
treatment with RIX has shown promising results (27, 28).
Unlike the known thyroidal side effects of immunomodu-
latory agents used in hepatitis C and cancer treatment, the 
immunomodulatory agents (anti-TNF-α and RIX) used in 
treatment of rheumatoid arthritis did not lead to significant 
changes in thyroid function nor autoimmunity. However, the 
well-established association between rheumatic diseases and 
thyroid autoimmunity necessitates continued monitoring of 
thyroid function in patients with rheumatoid arthritis and 
vice versa (5, 8, 29). Finally, it is advised to scrutinize each new 
immunomodulatory agent for its effect on thyroid as well as 
other autoimmune diseases and for each disease to be treated, 
in order to establish concise recommendations for follow-up of 
each agent and each disease (30).
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